Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 6/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073055 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KMT2AAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL4066367 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KMT2AAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL4062725 | 0.81 | ALDH1A1 (0.57) | ALDH1A1KMT2AAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL14027072 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KMT2AAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL4159326 | 0.71 | PTGDR2 (0.45) | KMT2APTGDR2MC4RKCNH2 | |
| SCHEMBL14027101 | 0.71 | MC4R (0.47) | ALDH1A1KMT2AHPGDL3MBTL1MEN1 | |
| SCHEMBL4068186 | 0.71 | PTGDR2 (0.45) | KMT2APTGDR2MC4RKCNH2 | |
| SCHEMBL4540122 | 0.71 | MC4R (0.46) | KMT2AMEN1MC4RKCNH2 | |
| SCHEMBL4362731 | 0.71 | KCNH2 (0.46) | KMT2AHPGDL3MBTL1SMN1; SMN2PTGDR2 | |
| SCHEMBL4362793 | 0.71 | KCNH2 (0.44) | KMT2AMC4RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1204645-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| WO-2001010842-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-15 | — | — | WO | claimed |
| WO-2009080351-A1 | COMPOUNDS WITH ANTI-EMETIC EFFECT | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072050-A1 | Compounds with anti-emetic effect | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1644337-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Gene Logic, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005121100-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | GENE LOGIC INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6699873-B1 | EATING DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1204645-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001010842-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | ALDH1A1 3912/4885KMT2A 1838/4885APOBEC3A 4800/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | ALDH1A1 3816/4885KMT2A 2114/4885APOBEC3A 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.